LGLaura Gallur

Laura Gallur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura Gallur has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • SF3B1 mutation significance in myeloid neoplasms without anaemia

    by Sergi Camarillas, Xavier Calvo, Esther Alonso, Alba Mesa, Lurdes Zamora, Eugenia Rivero, Evelin Casanova, Leonor Arenillas, Bárbara Tazón‐Vega, Marta Garrote, et al.

  • Top Cited Papers

    Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

    by Gloria Iacoboni, Víctor Navarro, Ana África Martín-López, Kai Rejeski, Mi Kwon, Katarzyna Aleksandra Jalowiec, Paula Amat, Juan Luis Reguera-Ortega, Laura Gallur, Viktoria Blumenberg, et al.

    PURPOSE: Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus guidelines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking. We report distinct outcomes after CAR T-cell therapy according to previous bendamustine exposure. METHODS: The study included CAR T-cell recipients from seven European sites. Safety, efficacy, and CAR T-cell expansion kinetics were analyzed according to preapheresis bendamustine exposure. Additional studies on the impact of the washout period and bendamustine dose were performed. Inverse probability treatment weighting (IPTW) and propensity score matching (PSM) analyses were carried out for all efficacy comparisons between bendamustine-exposed and bendamustine-naïve patients. RESULTS: The study included 439 patients with R/R LBCL infused with CD19-targeted commercial CAR T cells, of whom 80 had received bendamustine before apheresis. Exposed patients had significantly lower CD3+ cells and platelets at apheresis. These patients had a lower overall response rate (ORR, 53% v 72%; P < .01), a shorter progression-free survival (PFS, 3.1 v 6.2 months; P = .04), and overall survival (OS, 10.3 v 23.5 months; P = .01) in comparison with the bendamustine-naïve group. Following adjustment methods for baseline variables, these differences were mitigated. Focusing on the impact of bendamustine washout before apheresis, those with recent (<9 months) exposure (N = 42) displayed a lower ORR (40% v 72%; P < .01), shorter PFS (1.3 v 6.2 months; P < .01), and OS (4.6 v 23.5 months; P < .01) in comparison with bendamustine-naïve patients. These differences remained significant after IPTW and PSM analysis. Conversely, the cumulative dose of bendamustine before apheresis did not affect CAR-T efficacy outcomes. CONCLUSION: Recent bendamustine exposure before apheresis was associated with negative treatment outcomes after CD19-targeted CAR T-cell therapy and should be therefore avoided in CAR T-cell candidates.


  • Open Access

    Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL

    by Viktoria Blumenberg, Galina Busch, Stephan Baumann, Regina Jitschin, Gloria Iacoboni, Laura Gallur, Josu Iraola-Truchuelo, Eva Hoster, Michael Winkelmann, Konstantin Hellwig, et al.